Allurion Technologies, Inc. (NYSE:ALUR) ("Allurion" or the "Company"), a pioneer in metabolically healthy weight loss, today announced its financial results for the first quarter and provided a business update. Recent Company Highlights and Outlook Maintaining 2025 revenue guidance of approximately $30 million with a reduction of approximately 50% in operating expenses compared to 2024 First quarter revenue of $5.6 million and operating expenses of $11.4 million, a 37% decrease in operating expenses compared to prior year; adjusted operating expenses of $10.1 million, a 45% decrease compared to prior year Net operating loss of $7.3 million, a 36% reduction compared to prior year; adj

Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a company dedicated to ending obesity, today announced that it will report financial results for the first quarter 2025 on Wednesday, May 14, 2025. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET. To access the conference call by telephone, please dial (888) 330-3417 (domestic) or +1 646 960 0804 (international) and use Conference ID 1905455. To listen to the conference call via live audio webcast, please visit the Events section of Allurion's Investor Relations website at Allurion - Events & Presentations. A replay of the conferenc

Meeting to Now be Held on Thursday, April 10, 2025 at 12:00 pm Via Live Audio Webcast Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a company dedicated to ending obesity, today announced that its Special Meeting of Stockholders (the "Special Meeting"), originally scheduled for Friday, April 4, 2025, has been postponed. The Special Meeting is now scheduled to be held on Thursday, April 10, 2025 at 12:00 p.m. (Eastern Time) and will still be held virtually via live audio webcast at www.virtualshareholdermeeting.com/ALUR2025SM. The record date for the Special Meeting, March 14, 2025, remains unchanged and applies to the postponed Special Meeting. The Special Meeting

Allurion Technologies, Inc. (NYSE:ALUR) ("Allurion" or the "Company"), a company dedicated to ending obesity, today announced its financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update. Recent Company Highlights and Outlook Reported initial data on the combination of the Allurion Program with low-dose GLP-1s showing optimization of muscle mass and GLP-1 adherence and announced plans to perform additional prospective studies on the combination approach Fourth quarter 2024 revenue of $5.6 million and full year revenue of $32.1 million, consistent with preannouncement on January 14, 2025 Fourth quarter 2024 operating expenses of $19

Average Total Weight Loss of 20% With 15% Increase in Lean Body Mass After 8 Months of Combined Therapy Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a company dedicated to ending obesity, today announced initial results on the combination of the Allurion Program with low-dose GLP-1 therapy to optimize muscle mass and GLP-1 adherence. 52 patients treated with the Allurion Balloon were started on 0.25mg semaglutide after completing their first month of balloon therapy. The dose of semaglutide was increased to no greater than 1.0mg over the subsequent 6 months. After 8 months of this combination approach, average total body weight loss was 20.3%, and lean body mass

Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a company dedicated to ending obesity, today announced that it will report financial results for the fourth quarter 2024 on Wednesday, March 26, 2025. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET. To access the conference call by telephone, please dial (888) 330-3417 (domestic) or +1 646 960 0804 (international) and use Conference ID 1905455. To listen to the conference call via live audio webcast, please visit the Events section of Allurion's Investor Relations website at Allurion - Events & Presentations. A replay of the confer

Patent portfolio now exceeds 60 issued patents globally Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a company dedicated to ending obesity, today announced that it has received two Issue Notifications from the U.S. Patent and Trademark Office (USPTO) dated February 19, 2025 for U.S. Patent No. 12,246,163 titled "Automatic-Sealing Balloon-Filling Catheter System" and U.S. Patent No. 12,245,962 titled "Balloon Sealing and Fill Valve". These patents, both of which are scheduled to issue on March 11, 2025, provide additional claims for an enhanced, next-generation version of Allurion's proprietary Balloon technology for the treatment of obesity that includes an enhanc

Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a company dedicated to ending obesity, today announced that it will be participating in two upcoming investor conferences. Dr. Shantanu Gaur, Founder and Chief Executive Officer, will present at 9:10 a.m. ET and host one-on-one investor meetings throughout the day on March 3, 2025, at the 45th Annual TD Cowen Healthcare Conference in Boston, Massachusetts. Dr. Gaur will also host one-on-one investor meetings at the 37th Annual Roth Conference in Dana Point, California from March 16-18, 2025. A webcast of the presentation will be available in the Events & Presentations section of Allurion's investor relations website.

Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a company dedicated to ending obesity, today announced that it has closed its previously announced registered direct offering with institutional investors for the purchase and sale of 900,000 shares of the Company's common stock at a price of $5.23 per share and warrants to purchase up to 1,800,000 shares of common stock in a concurrent private placement. The warrants have an exercise price of $5.23 per share and will become exercisable immediately following the date of stockholder approval and expire on the fifth anniversary of receipt of such approval. The registered direct offering of common stock and the concurrent p

Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a company dedicated to ending obesity, today announced that it has entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of 900,000 shares of the Company's common stock at a price of $5.23 per share in a registered direct offering. In addition, the Company will issue to the investors warrants to purchase up to 1,800,000 shares of common stock in a concurrent private placement. The warrants have an exercise price of $5.23 per share and will become exercisable immediately following the date of stockholder approval and expire on the fifth anniversary of receip

4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

Mr. Johns has worked over two decades bringing leading GLP-1 weight loss drugs and other metabolic drugs to market Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Keith Johns to its Board of Directors effective September 2, 2024. "We are extremely excited to welcome Keith to the Allurion Board of Directors as we look to capitalize on the significant opportunity in front of us within the fast-growing obesity management space," said Dr. Shantanu Gaur, Allurion's Founder and CEO. "I believe having Keith as a sounding board as we leverage the opportunities created by GLP-1s will be a competitive advantage." Omar Ishrak, Al

Mr. Wild brings over 20 years of experience building profitable commercial organizations at leading healthcare brands Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Adrian Wild as SVP, International Commercial. Effective August 13, 2024, Mr. Wild assumed the role and will lead the Company's international commercial sales and operations functions. "We are thrilled to welcome Adrian to Allurion and add his expertise to our leadership team as we advance the company toward profitability," said Dr. Shantanu Gaur, Allurion's Founder and CEO. "Adrian joins us at an extremely important time – where the obesity market is expandi

Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Ojas A. Buch as its new Chief Operating Officer. Effective June 3, 2024, Ojas assumed the role of Chief Operating Officer and will lead the company's Research and Development, Manufacturing and Operations, Quality and Regulatory, and Business Development and Innovation functions. He will also play a crucial role in commercial functions while working closely with the Board and Executive Leadership Team. Ojas will provide strategic and execution-focused guidance aimed to help the company achieve major milestones and scale sustainably. With a 25-year track record in the health

Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of its newest board member and Audit Committee Chair, Milena Alberti-Perez, effective as of March 11, 2024. "Milena joins the Allurion board during an exciting time in the company's history and is a proven and dynamic leader, with deep experience as an operator and board member," said Dr. Shantanu Gaur, Allurion Founder and CEO. "Her perspective and guidance will be invaluable as Allurion furthers its mission to treat the one billion people around the world with obesity." Ms. Alberti-Perez previously served as Chief Financial Officer at Getty Images (NYSE:GETY) and CFO at Peng

Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Brendan Gibbons as its new Chief Legal Officer and corporate secretary. Brendan joins Allurion with nearly 20 years' experience as a chief legal and compliance officer at three separate public companies. Most recently, Brendan served as Executive Vice President and Chief Legal Officer at Acushnet Company, the parent company of Titleist and other golf brands and a global leader in product innovation, precision manufacturing, and performance. Prior to Acushnet, Brendan held similar roles at Wolverine Worldwide and Carter's, Inc. Before going in-house, Brendan worked at Ropes &